| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$524,299 ) |
| | 2025 | 2024 | TING THERAPEUTICS, INC. | 6868 NANCY RIDGE DR | SAN DIEGO | CA | 92121-2217 | SAN DIEGO | USA | R44DC019065 | Therapeutics to prevent aminoglycoside-induced hearing loss | 000 | 2 | NIH | 11/15/2024 | -$524,299 |
|
| Issue Date FY: 2024 ( Subtotal = $1,202,119 ) |
| | 2024 | 2024 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC019065 | Therapeutics to prevent aminoglycoside-induced hearing loss | 000 | 2 | NIH | 7/17/2024 | $524,300 |
| | 2024 | 2024 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018762 | Preclinical evaluation of an otoprotectant TT002 | 000 | 4 | NIH | 7/17/2024 | $326,372 |
| | 2024 | 2024 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018463 | CDK2 inhibitors for protecting hearing loss | 000 | 4 | NIH | 12/1/2023 | $351,447 |
|
| Issue Date FY: 2023 ( Subtotal = $1,107,103 ) |
| | 2023 | 2023 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018762 | Preclinical evaluation of an otoprotectant TT002 | 001 | 3 | NIH | 7/20/2023 | $565,771 |
| | 2023 | 2023 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018463 | CDK2 inhibitors for protecting hearing loss | 000 | 3 | NIH | 12/10/2022 | $541,332 |
| | 2023 | 2023 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018463 | CDK2 inhibitors for protecting hearing loss | 001 | 3 | NIH | 3/20/2023 | $0 |
| | 2023 | 2022 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018762 | Preclinical evaluation of an otoprotectant TT002 | 000 | 2 | NIH | 3/20/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,124,124 ) |
| | 2022 | 2022 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018463 | CDK2 inhibitors for protecting hearing loss | 000 | 2 | NIH | 11/4/2021 | $566,238 |
| | 2022 | 2022 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R44DC018762 | Preclinical evaluation of an otoprotectant TT002 | 000 | 2 | NIH | 7/26/2022 | $621,419 |
| | 2022 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018762 | Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics | 000 | 1 | NIH | 3/24/2022 | -$2,625 |
| | 2022 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC019065 | Therapeutics to prevent aminoglycoside-induced hearing loss | 000 | 1 | NIH | 7/13/2022 | -$17,786 |
| | 2022 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018463 | CDK2 inhibitors for protecting hearing loss | 000 | 1 | NIH | 12/7/2021 | -$43,121 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018762 | Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics | 000 | 1 | NIH | 4/7/2021 | $0 |
| | 2021 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC019065 | Therapeutics to prevent aminoglycoside-induced hearing loss | 000 | 1 | NIH | 5/13/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $668,711 ) |
| | 2020 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018762 | Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics | 000 | 1 | NIH | 3/26/2020 | $205,736 |
| | 2020 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018463 | CDK2 inhibitors for protecting hearing loss | 001 | 1 | NIH | 9/25/2020 | $0 |
| | 2020 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC019065 | Therapeutics to prevent aminoglycoside-induced hearing loss | 000 | 1 | NIH | 7/17/2020 | $242,322 |
| | 2020 | 2020 | TING THERAPEUTICS LLC | 9764 ASCOT DR | OMAHA | NE | 68114-3846 | DOUGLAS | USA | R43DC018463 | CDK2 inhibitors for protecting hearing loss | 000 | 1 | NIH | 12/9/2019 | $220,653 |
|
|
